Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 45,474

Document Document Title
WO/2013/124026
Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus  
WO/2013/122178
 The purpose of the present invention is to use a protein obtained by fusing a cancer-specific antigen and a cytokine as a prophylactic or therapeutic agent for cancer. A pharmaceutical composition for preventing or treating cancer, ...  
WO/2013/122029
The purpose of the present invention is to provide an aromatic ring compound exhibiting GPR40 agonist activity. The compound represented by formula (I) (refer to the description for information pertaining to each symbol in the formula) o...  
WO/2013/121440
The present invention discloses process for preparing benzisothiazol-3-yl- piperazin-l-yl-methyl-cyclo hexyl-methanisoindol-l,3-dione and intermediates thereof.  
WO/2013/122107
The present invention relates to: a compound represented by formula (1) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition which contains, as an active ingredient, the compound or a pharmaceutically acceptable sa...  
WO/2013/122408
The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis and, more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerati...  
WO/2013/122778
Disclosed is a method of treating or preventing a disease or disorder of the central nervous system (CNS) in a patient comprising administering transcranially, for example, directly to the skull, an effective amount of an anti-inflammato...  
WO/2013/120379
Provided in the present invention is the use of SBT in the preparation of an inhibitor of GSK-3β, and in particular in the preparation of medicines for preventing and treating Alzheimer's disease and senescence.  
WO/2013/122502
The invention relates to the field of medicine. The pharmaceutical composition for the treatment of neurodegenerative diseases, in particular amyotrophic lateral sclerosis, contains non-replicating nanoparticles which comprise the human ...  
WO/2013/120835
The present invention relates to isoindoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such isoindoline derivatives, and the u...  
WO/2013/120229
Disclosed is a method for preparing aqueous nanoparticle suspensions of derivatives of 4,9-dihydroxy-naphtho[2,3-b]furan aliphatic acid esters. The compositions and the uses of the aqueous nanoparticle suspensions prepared according to t...  
WO/2013/120896
The present invention relates to a compound for use in the prevention and/or treatment of a disease selected from a neurodegenerative disease, especially Alzheimer disease, and a disease, disorder or condition involving an activation of ...  
WO/2013/120980
The invention relates to novel compounds of Formula I: wherein A1, A2, A3, A4, A5, A6, R2, R4, R5, R6, R7, R8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof...  
WO/2013/121334
The present invention relates to compounds of formula I, use of these compounds to treat mental and neurological disorders, especially depressions and psychoses of different etiology and methods for their preparation. The compounds provi...  
WO/2013/123083
Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.  
WO/2013/120438
Disclosed is the use of an inverse agonist for α-subunit-containing γ-aminobutyric acid A receptor in the preparation of a medicine for the prevention, alleviation, or treatment of pain.  
WO/2013/118858
It is achieved successfully to obtain a polypeptide having improved stability compared with that of a parent polypeptide thereof by modifying at least one amino acid residue located in a loop domain in an Fc region of an antibody. In add...  
WO/2013/119794
Modified release formulations of viloxazine and methods of administering the same are disclosed. High- drug load formulations of viloxazine are further disclosed.  
WO/2013/119042
The present invention provides a composition for preventing and curing of neuropathic pain, comprising substance P. Substance P of the present invention shows mitigating, preventive and/or therapeutic effects on neuropathic pain.  
WO/2013/119791
Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune ...  
WO/2013/117693
Use of a compound of formula (I): 5-{5-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-1,3,4-oxadiazol -2-yl}-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4- b]pyridin-4-amine (I) or a pharmaceutically acceptable salt thereof for the treat...  
WO/2013/118845
Provided is a compound having AMPA receptor function-enhancing activity that is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), and the lik...  
WO/2013/118855
Provided is a novel compound having P2X3 and/or P2X2/3 receptor antagonist activity, for example, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In formula (I), R2 represents a hydrogen atom or the ...  
WO/2013/117789
The present invention relates to formulated xanthoxyline analogues for use in the treatment of neurodegenerative diseases, to some of said analogues, and also to methods for obtaining same and pharmaceutical compositions that comprise sa...  
WO/2013/119605
The present invention relates to the use of an Angiotensin II type 1 (AT1) receptor blocker for promoting sleep and/or the treatment of insomnia. It is based, at least in part, on the results of experiments performed using a validated ra...  
WO/2013/119800
The invention relates to methods of protecting against chronic stress in a subject and treating stress sensitive disorders in a subject by antagonizing ghrelin or ghrelin receptor.  
WO/2013/118854
Provided is a drug for the treatment and/or prevention of pain or a drug for the treatment and/or prevention of sodium channel-mediated diseases. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: Ar...  
WO/2013/117288
Compounds of the formula I in which U, V and W have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous s...  
WO/2013/117285
Compounds of the formula (I) in which R1, R2 and X have the meanings indicated in Claim 1, are inhibitors of TBK1 and ΙΚΚε and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.  
WO/2013/117022
A 2,2',6,6'-tetraisopropyl-4,4'-2-biphenol (hereinafter referred to as 2-biphenol) lipid microsphere preparation takes 2-biphenol as the active component, and is prepared by using oil for injection, emulsifiers, additives, and water for ...  
WO/2013/119985
Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral...  
WO/2013/113148
Disclosed is a siRNA use of the β3 adrenergic receptor blocker and the targeting β3 adrenergic receptor gene. The β3 adrenergic receptor is an important factor for regulating and controlling SIRT1, mTOR, and p53. The β3 adrenergic re...  
WO/2013/113774
This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory dise...  
WO/2013/114400
The present invention relates to compressed pharmaceutical compositions of atypical antipsychotics. Particularly the present invention relates to compressed pharmaceutical compositions of asenapine or pharmaceutically acceptable salts th...  
WO/2013/116413
The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and t...  
WO/2013/116325
The present invention provides methods and systems for reducing falls in patients that are recurrent fallers. Specifically, the compositions, systems, and methods can relate to Parkinson's disease patients, particularly such patients tha...  
WO/2013/115083
[Problem] The purpose of the present invention is to provide a medicinal agent effective for the treatment of fibromyalgia. [Solution] The present invention relates to a therapeutic agent for fibromyalgia, which comprises an effective am...  
WO/2013/116174
The present invention provides novel mGlu2/3 agonists of formula (I) useful in the treatment of neurological or psychiatric disorders.  
WO/2013/115163
A compound represented by formula (1) or a pharmaceutically acceptable salt thereof retains the main beneficial effects of paroxetine while having an improved CYP inhibitory action. (1) [In the formula, R1 is a hydrogen atom or a C1-6 al...  
WO/2013/116226  
WO/2013/116186
The present invention relates to a method for treating visual disorders mediated by lateral geniculate nucleus, superior colliculus and the visual cortex by administering to a patient in need of such treatment, compounds acting at the al...  
WO/2013/115535
The present invention relates to a novel crystalline acid addition salt of a tricyclo derivative compound or a hydride thereof, and to a production method therefor. The crystalline acid addition salt or the hydride thereof according to t...  
WO/2013/115534
The present invention relates to a composition for preventing or treating multiple sclerosis, which comprises as an active ingredient Clematidis radix extract or cortex Acanthopanacis (Acanthopanax) extract. The composition of the presen...  
WO/2013/115793
8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8- acyloxymethyl, 8-phosphates, 8(phosphoryloxy)methyl, and 8-carbamates derivatives thereof substituted at the 5-position are described as useful for iron chelation a...  
WO/2013/113141
Disclosed are new applications of the β3 adrenergic receptor agonist. The β3 adrenergic receptor agonist is an important factor for regulating and controlling SIRT1, mTOR, and p53. The β3 adrenergic receptor agonist can be used for pr...  
WO/2013/113107
Methods of stimulating neuron survival, axon growth and/or promoting axon regeneration of a neogenin expressing cell in a subject in need thereof are provided. The methods involve for example, administering to a subject in need thereof a...  
WO/2013/110134
The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperazine and diazepine compounds, compositions containing them and their u...  
WO/2013/112673
Synthetic voacangine, including in substantially enantiomerically enriched forms, and derivatives thereof are provided.  
WO/2013/110313
Compounds of formula (I) are provided wherein R1 represents H, CN and CF3; R2 represents 1-naphthyl, 3,5-dichlorophenyl, 4-(4-fluorophenylthio)phenyl or phenyl substituted with one or more substituent selected from halogen, methoxy, cyan...  
WO/2013/111014
The present invention provides methods for the treatment of neuronal loss in inflammatory bowel disorders (e.g., Crohn's disease or ulcerative colitis) comprising inhibition of pannexin-1 in a subject.  

Matches 701 - 750 out of 45,474